<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00029328</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-2020-01</org_study_id>
    <secondary_id>UMCC-0078;</secondary_id>
    <secondary_id>FD-R-002020-01</secondary_id>
    <nct_id>NCT00029328</nct_id>
  </id_info>
  <brief_title>Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation</brief_title>
  <official_title>Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of etanercept, and define the toxicity,&#xD;
      when administered to patients with acute non-infectious lung injury (idiopathic pneumonia&#xD;
      syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the last 2 decades, allogeneic bone marrow transplantation (BMT) has emerged as an&#xD;
      important treatment option for a number of malignant and non-malignant disorders.&#xD;
      Unfortunately, pulmonary dysfunction remains a frequent and severe complication of allogeneic&#xD;
      BMT. One of the main chemicals felt to cause lung damage is Tumor Necrosis Factor (TNF).&#xD;
      Etanercept is an experimental drug that attempts to block TNF lung damage. Patients will&#xD;
      undergo blood tests, x-rays, and a bronchoscopy with broncho-alveolar lavage prior to&#xD;
      treatment with etanercept to check for infection. If no infection is evident after 24 hours,&#xD;
      the etanercept will be started and administered twice weekly for 4 weeks by subcutaneous&#xD;
      injection. There will be weekly blood tests and bronchoscopy after the last drug dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date>September 2003</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>15</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Pneumonia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of acute idiopathic pneumonia syndrome (IPS) or sub-acute lung injury&#xD;
&#xD;
          -  At least 1 year of age for IPS stratum&#xD;
&#xD;
          -  At least 6 years of age for sub-acute lung injury stratum and able to perform formal&#xD;
             pulmonary function testing&#xD;
&#xD;
          -  At least 14 days since prior treatment with an investigational drug for&#xD;
             graft-versus-host disease&#xD;
&#xD;
          -  Previously treated with allogeneic stem cell or bone marrow transplantation for&#xD;
             primary disease&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Documented evidence of active systemic or pulmonary infection&#xD;
&#xD;
          -  Cardiogenic failure as cause of pulmonary dysfunction&#xD;
&#xD;
          -  Known hypersensitivity to etanercept&#xD;
&#xD;
          -  Currently receiving dialysis&#xD;
&#xD;
          -  Currently receiving inotropic medications except dopamine&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Cooke, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan, Ann Arbor, MI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2001</verification_date>
  <study_first_submitted>January 10, 2002</study_first_submitted>
  <study_first_submitted_qc>January 10, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2002</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>TNFR-Fc fusion protein</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Transplantation, Homologous</keyword>
  <keyword>Respiratory Function Tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

